Moderna’s Cancer Treatment: S&P 500 and VIX’s Unexpected Market Impact
724FinanceEge Kaan
Key Highlights
Moderna'nın yeni kanser tedavisi olan **mRNA-4157**, piyasada büyük bir heyecan yarattı. Tedavinin **90% oranında etkinliği** ve **önceki tedavilerden
Moderna’s new cancer treatment, mRNA-4157, has sparked significant market excitement. With an efficacy rate of 90% and fewer side effects than previous treatments, the company’s stock surged by 25%. This development triggered a VIX decline and a resurgence of the gamma squeeze, as investors began valuing the treatment’s potential. The S&P 500 options market also saw short-term pricing fluctuations.
The treatment’s success could boost Moderna’s earnings margins by 30%, while the VIX drop supported currency rates. This scenario increases the likelihood of the Federal Reserve delaying rate hikes. >
Related News & Analysis
View All →
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Inertia Enterprises Cuts Fusion Fuel Loading to Hours, Shaking the Energy Market
Patreon Unveils 30 New Features to Revolutionize Creator Ecosystem
Latest Market News
All News →Rising Yields Threaten to Burst the Stock-Market Bubble: How Markets Will React
Human Capital Resilience in the Age of AI: Implications for Financial Markets
![[ALKLC] ALTINKILIÇ GIDA VE SÜT SANAYİ TİCARET A.Ş.
Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu](/_next/image?url=%2Fuploads%2Fkap-default.png&w=3840&q=75)
[ALKLC] ALTINKILIÇ GIDA VE SÜT SANAYİ TİCARET A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu
Turkey Cuts Inflation Target from 75–80% to 30%: Bolat’s Bold Move
Hyperliquid Goes to the US: Regulatory and Market Shockwaves